New Course Form

https://myuk.uky.edu/sap/bc/soap/rfc?services=

Open in full window to print or save

Attachments:
Browse... No file selected.           Upload File

ID   Attachment
Delete 5259 PHR 957 INTEGRATED DRUGS AND DISEASES 4 - ONCOLOGY

First 1 Last

Select saved project to retrieve…

(*denotes required fields)

1. General Information
   a. * Submitted by the College of: Pharmacy
      Submission Date: 9/9/2015
   b. * Department/Division: Pharmacy
   c. * Contact Person Name: Frank Romanelli
      Email: froma2@email.uky.edu
      Phone: 257-4778
      Val Adams, Penni Black
      Email: val.adams@uky.edu
      Phone: 257-5202
   d. * Requested Effective Date: Semester following approval or Specific Term/Year
      Semester following approval OR Specific Term/Year
      1 Fall 2015
   e. Should this course be a UK Core Course?  Yes  No
      If YES, check the areas that apply:
      - Inquiry - Arts & Creativity
      - Composition & Communications - II
      - Inquiry - Humanities
      - Quantitative Foundations
      - Inquiry - Nat/Math/Phys Sci
      - Statistical Inferential Reasoning
      - Inquiry - Social Sciences
      - U.S. Citizenship, Community, Diversity
      - Composition & Communications - I
      - Global Dynamics

2. Designation and Description of Proposed Course.
   a. * Will this course also be offered through Distance Learning?  Yes  No
   b. * Prefix and Number: PHR 957
   c. * Full Title: Integrated Drugs and Diseases 4: Oncology
   d. Transcript Title (if full title is more than 40 characters):
   e. To be Cross-Listed with (Prefix and Number):
   f. * Courses must be described by at least one of the meeting patterns below. Include number of actual contact hours for each meetin
      Lecture 48  Recitation  Seminar
      Indep. Study  Clinical  Practicum
      Research  Residency  Studio
      Other
      If Other, Please explain:

   g. * Identify a grading system:
      - Letter (A, B, C, etc.)
      - Pass/Fail
      - Medicine Numeric Grade (Non-medical students will receive a letter grade)
      - Graduate School Grade Scale
h. * Number of credits:  4

i. * Is this course repeatable for additional credit?  Yes No
   If YES: Maximum number of credit hours:
   If YES: Will this course allow multiple registrations during the same semester? Yes No

j. * Course Description for Bulletin:
   This course will describe the pharmacology, medicinal chemistry, pathophysiology, and therapeutics as:
   of hematological and oncological illnesses so that students can design and manage drug-related care in
   patients with these disease states.

k. Prerequisites, if any:
   Completion of the second-year PharmD curriculum.

l. Supplementary teaching component, if any:
   Community-Based Experience Service Learning Both

3. * Will this course be taught off campus?  Yes No
   If YES, enter the off campus address:

4. Frequency of Course Offering.
   a. * Course will be offered (check all that apply): Fall Spring Summer Winter
   b. * Will the course be offered every year? Yes No
      If No, explain:

5. * Are facilities and personnel necessary for the proposed new course available?  Yes No
   If No, explain:

6. * What enrollment (per section per semester) may reasonably be expected?  1-40

7. Anticipated Student Demand.
   a. * Will this course serve students primarily within the degree program? Yes No
   b. * Will it be of interest to a significant number of students outside the degree prog? Yes No
      If YES, explain:

8. * Check the category most applicable to this course:
   Traditional – Offered in Corresponding Departments at Universities Elsewhere
   Relatively New – Now Being Widely Established
   Not Yet Found in Many (or Any) Other Universities

9. Course Relationship to Program(s).
   a. * Is this course part of a proposed new program? Yes No
      If YES, name the proposed new program:
   b. * Will this course be a new requirement for ANY program? Yes No
If YES, list affected programs:
PharmD new curriculum

10. Information to be Placed on Syllabus.

a. * Is the course 400G or 500?  ☐ Yes ☐ No
   If YES, the differentiation for undergraduate and graduate students must be included in the information required in 10.b. You must include additional assignments by the graduate students; and/or (ii) establishment of different grading criteria in the course for graduate students.

b. ☐ The syllabus, including course description, student learning outcomes, and grading policies (and 400G-/500-level grading differences) are attached.

---

11. Courses are typically made effective for the semester following approval. No course will be made effective until all approvals are received.
12. The chair of the cross-listing department must sign off on the Signature Routing Log.
13. In general, undergraduate courses are developed on the principle that one semester hour of credit represents one hour of classroom meeting per week for a semester, exclusive of any laboratory meeting. Labor is counted as at least two hours per week for a semester for one credit hour. (from SR 5.2.1)
14. You must also submit the Distance Learning Form in order for the proposed course to be considered for DL delivery.
15. In order to change a program, a program change form must also be submitted.

Rev 8/09
Course Description/Goal(s):

Describe the pharmacology, medicinal chemistry, pathophysiology, and therapeutics associated with hematological and oncological illnesses so that students can design and manage drug-related care plans for patients with these disease states.

Prerequisites:
Completion of the second-year of the College of Pharmacy curriculum

Student Learning Outcomes:

- Explain the pathophysiology and therapeutic approach(s) to commonly encountered cancers.
- Describe and discuss the pharmacology and medicinal chemistry of drugs used to manage commonly encountered cancers.
- Using patient history, laboratory data, and physical assessment findings differentiate between commonly encountered cancers.
- Synthesize information related to pharmacology, medicinal chemistry, and therapeutics in order to manage pharmacotherapeutic care plans.

Course Meeting Pattern and Location
Recitation M and T for 1.5 hours each
**Required Materials:**
Access to materials on the internet is required for both in- and out-of class research.

**Summary Description of Course Assignments**
IDD-Oncology will be delivered in a case-based, team-based learning format using the Patient Care Process as a foundation for teaching and learning. Each week will be divided to two Recitation sessions and one Think Day. Students can expect to spend Think Days with focused learning assignments that prepare them for understanding the vocabulary of cancer; drug information related to medicinal chemistry, cell signaling, and PK/PD/pharmacogenomics; and web-based decision-making guidelines for cancer therapy.

**Assessment**

<table>
<thead>
<tr>
<th>Grade</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>90 – 100%</td>
</tr>
<tr>
<td>B</td>
<td>80-89.9%</td>
</tr>
<tr>
<td>C</td>
<td>70-79.9%</td>
</tr>
<tr>
<td>E</td>
<td>&lt;70%</td>
</tr>
</tbody>
</table>

- SOAP notes 50%
- Final Exam 20%
- Competency quizzes 30%

*All exam/course related grades and assessment are final after 7 days after posting.

**Exam Schedule**

- Final exam Dec 1, 2018 8-10AM (BPC 124)

**Exam Policies**
Please use assigned seating. Bathroom breaks are allowed if an emergency arises.
ExamSoft® may be used for examinations, and you are responsible for full functionality of this software. If the exam is interrupted, College policies will be followed for resumption or make up.

IT Assistance: helpdesk@uky.edu
COP IT Assistance: pharmit@lsv.uky.edu, 257-1169

Course Policies:
Please see College Policy (student handbook) --

Communication:
Email communications will be addressed and answered within 3 business days.

Submission of Assignments:
Assignments may be due as paper submissions or using the Learning Management System. Assignments are due on the date assigned, unless you have an excused absence (see below). You can expect assignments to be returned within 7 days.

Attendance Policy:

Excused Absences:
College Policy (student handbook) --

Verification of Absences
Students may be asked to verify their absences in order for them to be considered excused. Senate Rule 5.2.4.2 states that faculty have the right to request “appropriate verification” when students claim an excused absence because of illness or death in the family. Appropriate notification of absences due to university-related trips is required prior to the absence.

Classroom Behavior Policies / Professionalism
“To describe someone as a ‘scholar’ is to acknowledge the many traits and abilities exhibited by an individual that are consistent with scholarship. Scholars (faculty and students alike) expect a certain degree of respect from other scholars regardless of the similarity or divergence of viewpoint and irrespective of age or experience. Faculty have the right – and the responsibility – to ensure that all academic discourse, both oral and written, occurs in a context characterized by respect and civility.”
From: Office of the Academic Ombudsman

Student behavior that detracts from the educational environment will not be tolerated. Examples of inappropriate behaviors include, but are not limited to: engaging in disrespectful debate with instructors or classmates; holding disruptive conversations with fellow classmates during class; reading newspapers or playing games during class; using cell-
phones in the classroom; sleeping during class meetings; attacks of a personal nature or statements/actions denigrating another on the basis of race, culture, gender, religion, sexual orientation, age, national/regional origin, disability or other such factors.
All actions taken due to inappropriate behavior will be documented and forwarded to the student record in the College of Pharmacy Student and Academic Affairs Office.

**Academic Integrity:**
Cheating and plagiarism will not be tolerated and will be prosecuted to the fullest extent of Honor Code and University regulations. All examinations will be taken in accordance with the College of Pharmacy Honor Code which can be found at the following address: http://pharmacy.mc.uky.edu/programs/pharmd/files/COP%20Student%20Handbook.pdf.

**Accommodations for Disabilities**
Any student seeking accommodations from the University must notify the Director of Student Success and Career Development in the College of Pharmacy of that disability, in writing, preferably before the beginning of the school year, **but in no case later than the third day of classes** for the fall/spring semester. If a disability develops during the school year for which accommodations are requested, the student must notify Academic and Student Affairs, in writing, as soon as he/she becomes aware of the disability. The student must also notify the coordinator of each course he/she is enrolled in of his or her anticipated accommodation in the same time frame. The student will be required to provide current documentation of the condition for which they require accommodation to the University Disability Resource Center: http://www.uky.edu/StudentAffairs/DisabilityResourceCenter/ (257-2754) before any accommodations can be instituted.

The Disability Resource Center will base provision of services to accommodate disability upon a review of current medical or psychological document and an assessment of the current needs and appropriate services. In addition to the student’s notification, request for accommodation and documentation will be kept confidential, but will be disclosed in the provision of the accommodation. Students having the same accommodation may be tested together. A student with documentation from previous semesters in the curriculum is not required to have his/her case re-evaluated by the Disability Resource Center. However, he/she must notify the coordinator of each course he/she is enrolled in of his or her accommodation in no case later than the third day of classes for the fall/spring semester.

**Religious Observances**
“Faculty shall give students the opportunity to make up work (typically, exams or assignments) when students notify them that religious observances prevent the students from doing their work at its scheduled time. Faculty shall indicate in their syllabus how much advance notice they require from a student requesting an accommodation. Faculty may use their judgment as to whether the observance in question is important enough to warrant an accommodation, although the presumption should be in favor of a student’s request. The Offices of Institutional Diversity, the Dean of Students, and the Ombud are available for consultation.” Thus faculty are to be flexible in allowing student observers to make up school
work missed on the official or commonly recognized high holy days. Supervisors are urged to show the same sensitivity regarding employees.

**On-line Course Evaluation Policy for Course Syllabi**

Regular course and instructor evaluations are required by state, university and college regulations. These evaluations are essential for improving student learning by providing feedback to faculty about their classroom presentations. Based on your feedback, important decisions are made about courses and how they are taught. This process CANNOT work without your input. Please complete a course and instructor’s evaluation for each of your courses.

Your individual responses are completely anonymous. However, the Office of Education Innovation can track who has or has not completed each evaluation and send reminder notices. Summary reports of aggregate data will be provided to the faculty after the semester is completed.

If you do not complete an evaluation, you will receive an incomplete grade (“I”) for the semester because you have not completed all of the course requirements. When you complete the course evaluation, the incomplete grade will be changed to the grade earned in the course.

*Syllabus is subject to change with sufficient notice.*

**Course Schedule**

<table>
<thead>
<tr>
<th>Weeks</th>
<th>Disease</th>
<th>Topics</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>None</td>
<td>Cancer vocabulary Guidelines</td>
</tr>
<tr>
<td>2</td>
<td>Bladder</td>
<td>Cytotoxics-med chem Supportive care-CINV</td>
</tr>
<tr>
<td>3</td>
<td>Colorectal</td>
<td>Cytotoxics-medchem Biologics-monoclonal Ab (Bev,Pan, Cetuximab) Neuropathy</td>
</tr>
<tr>
<td>4/5</td>
<td>Breast</td>
<td>Gene analysis for risk Biomarkers for therapy Hormonal therapies</td>
</tr>
<tr>
<td>6</td>
<td>Prostate</td>
<td>Humanistic decision-making Pharmaceutics</td>
</tr>
<tr>
<td>7/8</td>
<td>Lung</td>
<td>Cytotoxics-med chem Small molecule targeted agents Immunotherapy</td>
</tr>
<tr>
<td>9</td>
<td>Renal</td>
<td>Oral TKI/mTOR inhibitors</td>
</tr>
<tr>
<td>10</td>
<td>Melanoma</td>
<td>Cell signaling Immunotherapy</td>
</tr>
<tr>
<td></td>
<td>Pancreatic</td>
<td>Cytotoxics-med chem VTE Supportive care-QoL, nutrition</td>
</tr>
<tr>
<td>---</td>
<td>------------</td>
<td>-------------------------------------------------------</td>
</tr>
<tr>
<td>12</td>
<td>CML/CLL</td>
<td>Chronic diseases Biomarkers for therapy</td>
</tr>
<tr>
<td>13</td>
<td>Multiple myeloma</td>
<td>Proteasome inhibitors-pharmacology/medchem imids</td>
</tr>
<tr>
<td>14</td>
<td>Cervical/Ovarian</td>
<td>vaccine</td>
</tr>
<tr>
<td>15</td>
<td>transplant</td>
<td>Immunosuppression</td>
</tr>
<tr>
<td>16</td>
<td>Final</td>
<td></td>
</tr>
</tbody>
</table>
Background
The current Doctor of Pharmacy curricula at the University of Kentucky was implemented in 1996 and with few minor exceptions the degree program has essentially remained unchanged. As a component of the 2011-13 Collegiate Strategic Plan the faculty endorsed a broad scale curricular reform process. The decision to engage in a major revision of the curriculum was driven by both internal (lag time since major modifications) and external factors (role of technologic and learning/pedagogic advances). Beginning in July of 2011 the College constituted several committees and working groups to design a new curricular framework that would change both the content and delivery model associated with the current Doctor of Pharmacy degree program. These various working groups have involved faculty, students, staff, residents, and alumni. Additionally, the College’s external advisory board has received regular updates on curricular reform progress and, in turn, provided feedback and recommendations for additional changes or modifications. In May of 2014 the faculty and other parties participated in a Curricular Reform Retreat held at the Boone Center. The Content map of courses has undergone 11 different revisions (see Content 11.1 attachment). To date, Curricular Reform has involved 4 distinct phases. The goal for launch of the ‘new’ curriculum (with the first professional year) is projected for Fall 2016.

**Phase 1:** Establishment of new outcomes for the Doctor of Pharmacy Degree Program. These ‘new’ outcomes were adopted and modified from the 2014 Center for Advancement of Pharmaceutical Education (CAPE) Proposed PharmD curricular outcomes. Once these outcomes were adopted both a Content Map and Delivery model were designed. Phase 1 also involved a re-examination of existing pre-requisites with small modifications which were approved by the HCCC in 2014.

**Phase 2:** This phase involved the initial ‘build-up’ of new courses as defined by our content map. These build-ups were orchestrated by teams of faculty who proposed goals and objectives for each course as well as broad “teaching topics” that would be found within each course. These teams also made initial proposal for assessments within each course as well as projected credit hour allotments.

**Phase 3:** In this phase specific faculty members were assigned a ‘new’ course and after being provided with ‘build up’ documents from Phase 2 they were asked to formally assemble a course syllabus using a uniform template syllabus.
**Phase 4:** All proposed syllabi were then collected and mapped to intended outcomes as well as topical areas required by our accreditation agency (Accreditation Council of Pharmacy Education-ACPE). Courses were also each reviewed by the curriculum committee and referred to course directors for edits, modifications, and clarifications. Subsequently, all syllabi were approved/endorsed by the curriculum committee and forwarded to the faculty. At the May 2015 meeting of the College Faculty all syllabi were approved.

**Phase 5:** Submission to HCCC for approval of courses by professional year.

**Phase 6:** PY1 ramp-up, The Institute, Fall 2016 launch (see “on-going activities” below).

**Curricular Highlights (see Content 11.1 attachment)**

- The new curriculum spans 4 professional years with no changes having been made to the fourth professional year. The fourth professional year involves 42 weeks of advanced pharmacy practice experiences (APPEs).
- Content within the new curriculum will be delivered using a hybrid or blended-learning model involving recitation, mini-lectures, off-loaded content, inverted classrooms, workshops, projects, and cases. Personal accountability for learning will undergird our approach as will limited or no “re-teaching” of previously instructed course work.
- The first professional year is primarily composed of foundational course work.
- The new curriculum involves a more integrated rather than silo approach to instructing pharmacy practice. The existing curriculum teaches students medicinal chemistry, pharmacology, physiology, pathophysiology, and pharmacotherapy in a set of separate and distinct courses. Within the new curriculum all of these courses have been combined and modularized so that instruction centers around a core body system or disease state. Instruction is integrated rather than sequestered. The integrated modular instruction will occur in a series of courses dubbed as “Integrated Drugs and Disease (IDD).” IDD will begin in the first professional year and continue to the third professional year as topics increase in complexity.

  An example of IDD sequence involving HIV would involve instruction regarding normal immune physiology followed by the pathogenesis of HIV infection. Students would then be introduced to the medicinal chemistry of antiretrovirals, followed by the pharmacology of these agents. Lastly, students would learn the pharmacotherapeutic strategies and treatment guidelines for use of these drugs in managing acutely infected patients.

- Students will take part in a two-part course series designed to provide a foundation in scholarly inquiry. Scholarship I will introduce the fundamentals of basic inquiry while Scholarship II will require students to engage in the development of some faculty-mentored research, business, or clinical practice plan.
- iCATS 1.0 will remain a component of the new curriculum as defined by the UKs Center for Interprofessional Education (CPE).
- New curricular elements will include basic instruction in the differential diagnosis of low acuity primary care issues commonly encountered in the pharmacy setting, course work in
clinical reasoning and thought processes, and a course series dedicated to the enhancement of ‘soft skills.’

- The total projected credit hours for the new curriculum is estimated to be: 152 hours. The existing curriculum embodies 156 credit hours.

On-Going Activities

- Beginning in 2013 the College launched a faculty development seminar series labeled “CALIBRATE,” designed to prepare faculty for teaching in the new curriculum. Topical areas covered within this on-going seminar series have varied and included both internal as well as nationally recognized external speakers.

- PaCE or the ‘Patient Care Experience’ is a six semester sequence of courses intended to span the first three professional years of the new curriculum which will engender both simulated patient care encounters (laboratory exercises) and experiential training. The PaCE sequence is currently being revised and will be presented to the curriculum committee and faculty before being forward to the HCCC. To date plans are for PaCE to follow a “see one, do one, teach one” model where teams of first, second, and third professional year students work in teams to complete patient care related activities. Senior students within these teams will be given more supervisory responsibilities, while more junior students will be responsible for carrying out prescription orders or other patient related activities.

- STEPS: a component of assessment related to the new curriculum will be the incorporation of milestone exams or “STEPS” at the conclusion of each professional year. These exams will allow students to gauge their progress and learning across a professional year and will afford the ability to identify potential areas of weakness that could be remediated before progression to the next professional year. The development plan for these assessments is on-going.

- iPAD Initiative: The faculty are exploring adoption of an iPAD computing requirement for all students matriculating into the new curriculum. The use of a standardized iPAD platform would allow the faculty to better standardize teaching, accomplish content distribution, and conduct assessments.

- ExamSoft: The faculty have endorsed a move to ExamSoft® as the standard assessment software which will be used within the new curriculum. The use of ExamSoft® will allow for the standardization of all assessments, development of question banks, more rapid dissemination of feedback and grades, and mapping of individual questions to both outcomes as well as topical areas required by our accreditation agency. ExamSoft will also allow the faculty to provide students more robust statistical data in terms of their performance in specific areas or topics associated with any given course within the new curriculum.

- “The Institute”: As an extension of the CALIBRATE series, The Institute will involve a more intensive ‘boot camp’ approach to faculty and course development. The Institute will be a hands-on, multi-day workshop designed as a more rigorous training experience for faculty who will be teaching in the first professional year in Fall 2016. As the curriculum fans out, second and then third professional year teaching faculty will be invited to participate within The Institute.
## Content 11.2

<table>
<thead>
<tr>
<th>FALL</th>
<th>SPRING</th>
<th>FALL</th>
<th>SPRING</th>
<th>FALL</th>
<th>SPRING</th>
<th>FALL</th>
<th>SPRING</th>
<th>FAL/SPRING</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>PY1</strong></td>
<td><strong>PY2</strong></td>
<td><strong>PY3</strong></td>
<td><strong>PY4</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>FALL</strong></td>
<td><strong>SPRING</strong></td>
<td><strong>FALL</strong></td>
<td><strong>SPRING</strong></td>
<td><strong>FALL</strong></td>
<td><strong>SPRING</strong></td>
<td><strong>FALL</strong></td>
<td><strong>SPRING</strong></td>
<td><strong>FAL/SPRING</strong></td>
</tr>
<tr>
<td>Transitions in Pharmacy</td>
<td>Cells &amp; Molecules</td>
<td>Foundations in Pharm Science I</td>
<td>Wellness &amp; Health Promotion I</td>
<td>Clinical Reasoning</td>
<td>Pharmacy as a Profession</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(PHR 911-001)</td>
<td>(PHR 912-001)</td>
<td>(PHR 913-001)</td>
<td>(PHR 914-001)</td>
<td>(PHR 915-001)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IDD 1 (ID)</td>
<td>IDD 2 (Neuro)</td>
<td>IDD 3 (Cardio)</td>
<td>IDD 4 (Psychiatry)</td>
<td>IDD 5 (Crit Care)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(PHR 926-001)</td>
<td>(PHR 935-001)</td>
<td>(PHR 946-001)</td>
<td>(PHR 956-001)</td>
<td>(PHR 966-001)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IDD 1 (GI/Nutr)</td>
<td>IDD 2 (Rheum)</td>
<td>IDD 3 (GU)</td>
<td>IDD 4 (Oncology)</td>
<td>PTx Applications in Special Pops</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(PHR 927-001)</td>
<td>(PHR 937-001)</td>
<td>(PHR 947-001)</td>
<td>(PHR 957-001)</td>
<td>(PHR 967-001)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kinetics and Dynamics</td>
<td>IDD 2 (Endocrine)</td>
<td>IDD 3 (Pulm)</td>
<td>IDD 5 (Crit Care)</td>
<td>Operations &amp; Fin Mgmt</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(PHR 921-001)</td>
<td>(PHR 938-001)</td>
<td>(PHR 948-001)</td>
<td>(PHR 955-001)</td>
<td>(PHR 964-001)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Foundations in Pharm Science II</td>
<td>Policy, Outcomes &amp; Public Health</td>
<td>Leadership in Pharmacy</td>
<td>Scholarship I</td>
<td>EBM</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(PHR 922-001)</td>
<td>(PHR 933-001)</td>
<td>(PHR 945-001)</td>
<td>(PHR 951-001)</td>
<td>(PHR 965-001)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Wellness &amp; Health Promotion II</td>
<td>Elective</td>
<td>Elective</td>
<td>Elective</td>
<td>Elective</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(PHR 923-001)</td>
<td>(PHR 951-001)</td>
<td>(PHR 951-001)</td>
<td>(PHR 961-001)</td>
<td>(PHR 961-001)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Elective</td>
<td>Elective</td>
<td>Elective</td>
<td>Elective</td>
<td>Elective</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(PHR 910-001)</td>
<td>(PHR 920-001)</td>
<td>(PHR 930-001)</td>
<td>(PHR 940-001)</td>
<td>(PHR 960-001)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PaCE</td>
<td>PaCE</td>
<td>IPPE</td>
<td>PaCE</td>
<td>PaCE</td>
<td>PaCE</td>
<td>PaCE</td>
<td></td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>3</td>
<td>2</td>
<td>3</td>
<td>4</td>
<td>5</td>
<td>6</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(PHR 910-001)</td>
<td>(PHR 920-001)</td>
<td>(PHR 928-001)</td>
<td>(PHR 930-001)</td>
<td>(PHR 940-001)</td>
<td>(PHR 950-001)</td>
<td>(PHR 960-001)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>19</td>
<td>19</td>
<td>4</td>
<td>16</td>
<td>17</td>
<td>17</td>
<td>18</td>
<td>42</td>
<td></td>
</tr>
</tbody>
</table>